Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value.
OpenEvidence’s $12 billion valuation reflects investor confidence in its bottom-up, doctor-first model. It has driven rapid adoption, with more than 757,000 clinicians using the startup’s free AI medical search tool regularly. That scale is paired with targeted pharmaceutical advertising that’s already pushed the company past a $100 million revenue run rate.
At the ViVE conference in LA, Smarter Technologies Chief Medical Officer Ruben Amarasingham MD talked with Katie Adams about the company's larger goals for AI: to improve the accuracy of data and make healthcare less burdensome for physicians and clinicians.
There are currently 97 global digital health companies that are considered unicorns. But getting caught up with the idea of digital health unicorns isn’t very sustainable, according to Emilly Melton, managing partner at Threshold Ventures. Instead of focusing too much on their valuations, she recommended that startups simply focus on getting the capital they need in order to reach the next stage of inflection.
With plans to sell 60 million shares of common stock, Bright Health will price its IPO between $20 and $23 per share. It will trade on the New York Stock Exchange under the symbol "BHG," according to a recent SEC filing.
The newly crowned unicorn's insurance product enables members to shop for medical services and pay directly for care. The company raised $125 million in a recent funding round, boosting its valuation, which it will use to increase its footprint and launch new products.
Investors turn down more than 95 percent of the deals they see. They are looking for reasons to quickly reject them. Here are a few examples of how startups can avoid missteps that can cost their businesses funding.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
What should executives of health IT companies focus on to break through the noise and secure one of the desired exit valuation outcomes?